



# BARDA INDUSTRY DAY

## Influenza and Emerging Infectious Diseases Division

Robert Johnson, PhD

Director, Influenza and Emerging Infectious Diseases


October 29, 2018

October 29-30, 2018 | Grand Hyatt • Washington, D.C.




# Influenza: Domestic Impact


## Deaths (Thousands)




## Case Fatality (%)



## Economic Loss (Billion \$)




## Hospitalizations (Million)



Saving Lives. Protecting Americans.

# Improving Preparedness and Response




# Key Target Milestones



# Ongoing Influenza Countermeasure Initiatives

## Domestic Capacity Gaps



Antigen supply


Adjuvant supply



Production

Better, Faster, Flu Vaccines

## Speed/Flexibility



One develops disease

## Efficacy




# Pre-pandemic Vaccines for Pandemic Preparedness

Procure Pre-pandemic Vaccines and Adjuvants




Monitor Stability of Vaccines & Adjuvants Tests & clinical trials



Flexible & Optimized Stockpile: Antigen +Adjuvant Studies



Broader Protection: Induction of cross-protective immunity



# Diagnostics



# Therapeutics




**Pimodivir**




**Baloxavir**



**Monoclonal antibodies**




## Immune modulators



**One of many potential pathways to target**

*Galani 2017 Immunity. 46(5):875*

# Respiratory Protective Devices



# Sustainability



**1st Valley of Death:  
Advanced Development  
and Licensure**

**2nd Valley of Death:  
Sustainment/Sustainability**






**Seasonal  
Influenza  
Preparedness**

**Pandemic  
Influenza  
Preparedness**



*Saving Lives. Protecting Americans.*

# End-to-End Strategy





**Emerging  
Infectious Diseases  
Preparedness**

**Pandemic  
Influenza  
Preparedness**



*Saving Lives. Protecting Americans.*